Smartphone-guided weight loss program for people with coronary heart disease and obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized controlled trial enrolling about 136 patients over one year to compare software-based personalized diet and exercise guidance versus routine care. Participants in the intervention arm receive baseline evaluations by cardiology, dietetics, and rehabilitation specialists and a tailored plan delivered via an app with a target of 10% weight loss in six months. Daily energy targets are calculated (BEE * 1.3 - 500 kcal) and the software produces individualized meal plans and progressive exercise prescriptions after initial training in resistance and aerobic training. Control participants receive routine dietary and exercise advice without the weight-loss software, and all other clinical care follows local practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age range: 18-65 years old .
2. History of coronary heart disease confirmed by coronary angiography or coronary CTA, showing ≥50% stenosis in at least one major coronary artery (left main coronary artery, left anterior descending artery, left circumflex artery, right coronary artery); or a definite history of myocardial infarction, or prior coronary revascularization (PCI or CABG).
3. BMI: Body Mass Index (BMI) ≥ 28 kg/m²
4. Weight loss willingness: Has the intention to lose weight
5. Smartphone proficiency: Able to use a smartphone.
6. Daily living ability: Capable of performing basic activities of daily living independently.
7. Informed consent: Voluntarily participates in the study, signs a written informed consent form, and is willing to cooperate with follow-up

Exclusion Criteria:

1. Unstable angina pectoris or acute myocardial infarction occurring within the previous month;
2. Comorbid endocrine or neurological diseases, cancer, or a history of bariatric surgery that affect body weight; or long-term use of medications that impact body weight;
3. Comorbid diseases that affect exercise capacity, such as severe cardiopulmonary diseases or osteoarthritic conditions;
4. Comorbid diseases that affect diet, such as severe mental disorders, bulimia or anorexia nervosa, or cognitive dysfunction;
5. Significant liver or kidney dysfunction, defined as: glomerular filtration rate \< 60 ml/(min·1.73m²) or undergoing dialysis; alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 3 times the upper limit of the normal range specified by the research center;
6. Severe language, psychological, or physical disabilities that prevent participation in the protocol;
7. Pregnant or lactating women, or individuals of childbearing potential who are unwilling/unable to use effective contraceptive measures;
8. Participation in other interventional clinical trials;
9. Body weight change exceeding 5% within the past year;
10. Patients with a habit of long-term high-intensity exercise(more than 2 sessions per week of high-intensity endurance training, or more than 3 sessions per week of moderate-intensity endurance training);
11. Patients deemed unsuitable for participation in the study by the researchers.

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: yuan yu, doctor
• Email: smileyuyuan@sina.cn
• Phone: 86➕17801013954

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pistachio snacking to improve metabolic flexibility in adults with overweight

  We will try eating pistachios for a few days to see if it helps adults with overweight or obesity use energy better at rest, during exercise, and after exercise.

  Recruiting University of South Carolina · Columbia, South Carolina · NCT07340125

• THDBH120 injections for weight loss in adults with overweight or obesity

  This study will test whether THDBH120 injections help adults who are overweight or obese lose more weight than a placebo over 26 weeks.

  Recruiting Phase 2 Tonghua Dongbao Pharmaceutical Co.,Ltd · Changsha · NCT07036601

• Evaluating MWN109 Injection in Healthy Volunteers

  This study is testing the safety of a new injection called MWN109 in healthy volunteers to see how well they tolerate it compared to a placebo.

  Recruiting Phase 1 Shanghai Minwei Biotechnology Co., Ltd · Melbourne, Victoria · NCT06859853

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.